American Healthcare REIT, Inc.
AHRDrugs in Pipeline
26
Phase 3 Programs
19
Upcoming Catalysts
2
Next Catalyst
Jun 30, 2026
10dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Regulatory — North American Coral Snake Antivenin (Micrurus fulvius) (Equine Origin)
For North American coral snake envenomation. FDA granted an expiration date extension for North American Coral Snake Antivenin Lot CL6814, extending its shelf life through June 30, 2026. This is a routine regulatory maintenance action for an existing product.
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Proparacaine Ophthalmic
Anesthesia, Local
Iron Dextran
Anemia
Venofer and stable erythropoietin (EPO) regimen
Anemia
Iron Sucrose (Venofer)
Iron Deficiency Anemia
VIT-45
Anemia
AG-920
Anesthesia, Local
Standard Medical Care (SMC) for the treatment of IDA
Anemia
Oral iron tablets
Anemia
Ferrous Sulfate
Iron Deficiency Anemia
Venofer
Anemia
Ferric carboxymaltose
Iron Deficiency Anemia
Injectafer
Iron Deficiency
Iron Sucrose + Erythropoietin
Anemia
Ferrous Sulfate tablets
Anemia
Taxoprexin
Non-Small Cell Lung Cancer
SPRIX
Pain
Ferric Carboxymaltose (FCM)
Anemia
iron sucrose injection USP
Anemia
Standard Medical Care (SMC)
Anemia
Iron Dextran Injection
Iron Deficiency Anemia
Iron Sucrose injection
Anemia
AOBO-001
Overactive Bladder
Ketorolac tromethamine
Postoperative Pain
dehydrated alcohol
Prostate Disease
Cohort I
Restless Legs Syndrome
Iron Sucrose / Iron Dextran
Iron Deficiency Anemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Proparacaine Ophthalmic | Phase 3 | Anesthesia, Local | - | - |
Iron Dextran | Phase 3 | Anemia | - | - |
Venofer and stable erythropoietin (EPO) regimen | Phase 3 | Anemia | - | - |
Iron Sucrose (Venofer) | Phase 3 | Iron Deficiency Anemia | - | - |
VIT-45 | Phase 3 | Anemia | - | - |
AG-920 | Phase 3 | Anesthesia, Local | - | - |
Standard Medical Care (SMC) for the treatment of IDA | Phase 3 | Anemia | - | - |
Oral iron tablets | Phase 3 | Anemia | - | - |
Ferrous Sulfate | Phase 3 | Iron Deficiency Anemia | - | - |
Venofer | Phase 3 | Anemia | - | - |
Ferric carboxymaltose | Phase 3 | Iron Deficiency Anemia | - | - |
Injectafer | Phase 3 | Iron Deficiency | - | - |
Iron Sucrose + Erythropoietin | Phase 3 | Anemia | - | - |
Ferrous Sulfate tablets | Phase 3 | Anemia | - | - |
Taxoprexin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
SPRIX | Phase 3 | Pain | - | - |
Ferric Carboxymaltose (FCM) | Phase 3 | Anemia | - | - |
iron sucrose injection USP | Phase 3 | Anemia | - | - |
Standard Medical Care (SMC) | Phase 3 | Anemia | - | - |
Iron Dextran Injection | Phase 2 | Iron Deficiency Anemia | - | - |
Iron Sucrose injection | Phase 2 | Anemia | - | - |
AOBO-001 | Phase 2 | Overactive Bladder | - | - |
Ketorolac tromethamine | Phase 2 | Postoperative Pain | - | - |
dehydrated alcohol | Phase 2 | Prostate Disease | - | - |
Cohort I | Phase 2 | Restless Legs Syndrome | - | - |
Iron Sucrose / Iron Dextran | Phase 2 | Iron Deficiency Anemia | - | - |